382 related articles for article (PubMed ID: 35141700)
1. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
2. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
3. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
4. Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Koola MM
Prim Care Companion CNS Disord; 2018 Mar; 20(2):. PubMed ID: 29570959
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
6. Integrative Pharmacology in the Treatment of Substance Use Disorders.
Donlon J; Kumari P; Varghese SP; Bai M; Florentin OD; Frost ED; Banks J; Vadlapatla N; Kam O; Shad MU; Rahman S; Abulseoud OA; Stone TW; Koola MM
J Dual Diagn; 2024; 20(2):132-177. PubMed ID: 38117676
[TBL] [Abstract][Full Text] [Related]
7. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
8. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.
Koola MM
Schizophr Res Cogn; 2016 Jun; 4():4-9. PubMed ID: 27069875
[TBL] [Abstract][Full Text] [Related]
9. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
[TBL] [Abstract][Full Text] [Related]
10. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.
Myint AM; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():304-13. PubMed ID: 24184687
[TBL] [Abstract][Full Text] [Related]
11. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
12. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.
Koola MM; Nikiforuk A; Pillai A; Parsaik AK
J Geriatr Care Res; 2018; 5(2):57-67. PubMed ID: 30984874
[TBL] [Abstract][Full Text] [Related]
13. Role of d-amino acid oxidase in the production of kynurenine pathway metabolites from d-tryptophan in mice.
Notarangelo FM; Wang XD; Horning KJ; Schwarcz R
J Neurochem; 2016 Feb; 136(4):804-814. PubMed ID: 26661897
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan and Kynurenine Pathway Metabolites in Animal Models of Retinal and Optic Nerve Damage: Different Dynamics of Changes.
Fiedorowicz M; Choragiewicz T; Thaler S; Schuettauf F; Nowakowska D; Wojtunik K; Reibaldi M; Avitabile T; Kocki T; Turski WA; Kaminska A; Grieb P; Zrenner E; Rejdak R; Toro MD
Front Physiol; 2019; 10():1254. PubMed ID: 31632294
[TBL] [Abstract][Full Text] [Related]
16. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
Song P; Ramprasath T; Wang H; Zou MH
Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
[TBL] [Abstract][Full Text] [Related]
17. Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.
Koola MM
Mol Neuropsychiatry; 2018 Dec; 4(3):134-148. PubMed ID: 30643787
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Prenatal Kynurenine Metabolism Using Tissue Slices: Focus on the Neosynthesis of Kynurenic Acid in Mice.
Notarangelo FM; Beggiato S; Schwarcz R
Dev Neurosci; 2019; 41(1-2):102-111. PubMed ID: 31117076
[TBL] [Abstract][Full Text] [Related]
19. Kynurenic Acid Levels and Kynurenine Aminotransferase I, II and III Activities in Ganglia, Heart and Liver of Snail Helix Pomatia.
Kronsteiner C; Baran H; Kepplinger B
Cell Physiol Biochem; 2023 Aug; 57(4):279-297. PubMed ID: 37597169
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Notarangelo FM; Wilson EH; Horning KJ; Thomas MA; Harris TH; Fang Q; Hunter CA; Schwarcz R
Schizophr Res; 2014 Jan; 152(1):261-7. PubMed ID: 24345671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
